Oxford Researchers Identify First Drug Proven to Reduce COVID Fatalities
Oxford University researchers announced on Tuesday that after a clinical trial of dexamethasone, a low-cost steroid treatment, they had found the first proven life-saving coronavirus treatment that reduced the risk of death for coronavirus patients with ventilators and by a third a fifth for those who have oxygen.
The study, which is part of the UK's Recovery Trial project to identify existing treatments for COVID-19, compared approximately 2,000 hospitalized patients who received dexamethasone to almost 4,000 patients who did not receive the drug.
In patients with ventilators, the risk of death was reduced from 40 to 28 percent, while in patients who needed oxygen, the risk of death was reduced from 25 to 20 percent.
Break: Oxford researchers find the first drug has been shown to reduce deaths from Covid
The inexpensive steroid dexamethasone reduced death in ventilated patients by a third
At the start of the pandemic, it could have saved some 5,000 lives in the UK
It costs about £ 5 - about £ 40 saves a life
3:00 p.m. - June 16, 2020
Twitter Ads info and privacy
1,146 people talk about it
“This is the only drug that has been shown to reduce mortality and significantly reduce it. This is a big breakthrough, ”said Dr. Peter Horby, chief investigator of the study, made a statement. The lead researcher Dr. Martin Landray added that the low cost of the drug would make it even more effective.
“There is a clear, clear advantage. Treatment lasts up to 10 days of dexamethasone and costs around GBP 5 per patient. So it essentially costs £ 35 to save a life. This is a drug that is available worldwide, ”he said, stressing that one life could be saved for eight patients with ventilators treated with the drug.
The only other drug that is promising in a clinical setting for the treatment of coronavirus is Remdesivir, an experimental antiviral treatment that has shown promise in treating patients at the start of the infection.
Oxford researchers have also made significant progress with a vaccine following positive studies with rhesus monkeys that were healthy after 28 days, despite being exposed to large amounts of coronavirus, which made the control group sick.
Oxford University researcher John Bell, who leads the project, said in May that the vaccine's ability to "generate strong antibody responses will likely be fine," but the verdict on whether it is a safe treatment would be still unclear.
"We are pretty sure we will get a signal by June whether this will work or not," said Bell.
More from National Review
Treatment with antiviral coronavirus shows the first signs of success in the Chicago Hospital study
Covid patients who tested positive after recovery are no longer infectious according to study results
"It's getting worse": Leading disease expert warns coronavirus ten times more deadly than flu
Click to receive the most important news as a notification!
The 9 Best Marshalls Shopping Secrets, Revealed - Tips to Save Money at Marshalls
Sofia Richie Demonstrates How to Elevate Affordable Loungewear In Sharp Glowing Pumps
'They only care about votes': As millions slip into poverty, voting may be the only leverage for a 2nd stimulus check
What to make of Bill Belichick’s odd comments about N’Keal Harry
Push to identify Biden allegations as Russia disinformation ‘has been repudiated': Former federal prosecutor
6 vaccine experts told us how they'll decide whether to get a coronavirus shot